Evidence Based Medicine Research Center, Endocrinology and Metabolism Clinical Science Institute, Tehran University of Medical Sciences, Tehran, Iran.
Islamic Azad University, Faculty of Medicine, Yazd, Iran.
Curr Rev Clin Exp Pharmacol. 2022;17(2):135-143. doi: 10.2174/2772432816666211012092112.
Subacute granulomatous thyroiditis (SAGT) is an inflammatory disease due to viral infections. Glucocorticoids, especially prednisolone (PSL), are one of the first approaches in the treatment of patients with SAGT. To date, no study has determined the lowest effective dose of prednisolone with the lowest recurrence rate in the treatment of SAGT. This study aimed to use meta-analysis methods to identify the appropriate dosage of prednisolone with the lowest recurrence rate in the treatment of patients with SAGT.
This study was conducted according to the PRISMA checklist in February 2021. Two independent researchers performed a search for relevant literature published before March 2021 in English databases, including Scopus, MEDLINE (via PubMed), Web of Science, Cochrane Library, Google Scholar, EMBASE, and also Persian electronic databases including SID, Iran medex, Magiran, and Irandoc. The search algorithm was initially developed by using a combination of MeSH terms, keywords, and also Boolean operators ("AND"; "OR"; "NOT"): Subacute thyroiditis, De Quervain Thyroiditis, Glucocorticoids, Prednisolone, Recurrence, and Meta-Analysis. All statistical analyses were performed using STATA 15.0 (StataCorp LLC, College Station, TX, USA) and SPSS 17.0. A random-effects model based on Metaprop was applied for the Meta-analysis. To assess heterogeneity between studies, the chi-squared test and I2 index were used, and for evaluating publication bias, funnel plots and Egger tests were performed.
The overall recurrence rate was 14.72% [95% CI: 9.63- 20.58] and there was a significant heterogeneity among the studies [I2 = 69.56%; P=0.000]. To evaluate the lowest effective dose of prednisolone, we divided the studies into two groups based on the mean initial dose of prednisolone: less than or equal to 20 mg/day (group one) and greater than 20 mg/day (group two). The recurrence rate in group 1 was 11% [95% CI: 5.7- 16.2] and in group 2 was 23.6% [95% CI: 11.5- 35.6]. Significant correlations were observed between the initial mean dose of PSL and recurrence rate (r= 0.71; P= 0.013). Begg's funnel plot had no evidence of publication bias in these studies (p=0.160).
According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis.
亚急性肉芽肿性甲状腺炎(SAGT)是一种由病毒感染引起的炎症性疾病。糖皮质激素,尤其是泼尼松龙(PSL),是治疗 SAGT 患者的首选方法之一。迄今为止,尚无研究确定治疗 SAGT 时泼尼松龙的最低有效剂量和最低复发率。本研究旨在使用荟萃分析方法确定治疗 SAGT 患者时泼尼松龙的最佳剂量和最低复发率。
本研究于 2021 年 2 月按照 PRISMA 清单进行。两名独立研究人员在 2021 年 3 月之前在英语数据库中搜索了相关文献,包括 Scopus、MEDLINE(通过 PubMed)、Web of Science、Cochrane 图书馆、Google Scholar、EMBASE,以及波斯语电子数据库,包括 SID、Iranmedex、Magiran 和 Irandoc。搜索算法最初是通过使用 MeSH 术语、关键词和布尔运算符(“AND”;“OR”;“NOT”)组合开发的:亚急性甲状腺炎、De Quervain 甲状腺炎、糖皮质激素、泼尼松龙、复发和荟萃分析。所有统计分析均使用 STATA 15.0(StataCorp LLC,德克萨斯州立大学,美国)和 SPSS 17.0 进行。基于 Metaprop 的随机效应模型用于荟萃分析。为了评估研究之间的异质性,使用卡方检验和 I2 指数,为了评估发表偏倚,使用漏斗图和 Egger 检验。
总体复发率为 14.72%[95%CI:9.63-20.58],研究之间存在显著异质性[I2=69.56%;P=0.000]。为了评估泼尼松龙的最低有效剂量,我们根据泼尼松龙的初始平均剂量将研究分为两组:≤20mg/天(组 1)和>20mg/天(组 2)。组 1的复发率为 11%[95%CI:5.7-16.2],组 2的复发率为 23.6%[95%CI:11.5-35.6]。PSL 的初始平均剂量与复发率之间存在显著相关性(r=0.71;P=0.013)。这些研究中的 Begg 漏斗图没有证据表明存在发表偏倚(p=0.160)。
根据这项荟萃分析的结果,15 至 20mg/天的泼尼松龙是治疗亚急性肉芽肿性甲状腺炎时最有效剂量和最低复发率的剂量。